In the last 12 months, insiders at Arbutus Biopharma Corp ($ABUS) filed 63 transactions with the SEC: 0 open-market purchases totaling $0 and 9 sales totaling $363,142. Net insider sentiment: net selling.
Arbutus Biopharma Corp operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- McElhaugh Michael J. (Interim President & CEO) — 6 transactions totaling $101,607
- HASTINGS DAVID C (Chief Financial Officer) — 8 transactions totaling $95,011
- Sims Karen (Chief Medical Officer) — 7 transactions totaling $73,597
- MANCHESTER KEITH S (Director) — 5 transactions totaling $63,390
- Naftzger J. Christopher (General Counsel and CCO) — 6 transactions totaling $37,206
View all SEC Filings for Arbutus Biopharma Corp (ABUS).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Androski Lindsay | President and CEO | A | Stock Option (Right to Buy) | 71700 | $0.00 | 71,700.0000 | 192,324,017 | 9999.99% | 0.04% |
| Feb. 2, 2026 | Androski Lindsay | President and CEO | A | Common Shares | 28000 | $0.00 | 28,000.0000 | 192,324,017 | 9999.99% | 0.01% |
| Feb. 2, 2026 | Nguyen Tuan | Chief Financial Officer | A | Stock Option (Right to Buy) | 188400 | $0.00 | 188,400.0000 | 192,324,017 | 9999.99% | 0.10% |
| Feb. 2, 2026 | Nguyen Tuan | Chief Financial Officer | A | Common Shares | 73500 | $0.00 | 73,500.0000 | 192,324,017 | 9999.99% | 0.04% |
| Aug. 4, 2025 | Sawhney Roger | Director | A | Stock Option (Right to Buy) | 157600 | $0.00 | 157,600.0000 | 191,480,188 | 9999.99% | 0.08% |
| March 31, 2025 | Nguyen Tuan | Chief Financial Officer | A | Stock Option (Right to Buy) | 750000 | $0.00 | 750,000.0000 | 191,480,188 | 9999.99% | 0.39% |
| March 31, 2025 | Nguyen Tuan | Chief Financial Officer | A | Stock Option (Right to Buy) | 750000 | $0.00 | 750,000.0000 | 191,480,188 | 9999.99% | 0.39% |
| March 18, 2025 | Androski Lindsay | President and CEO | A | Stock Option (Right to Buy) | 310422 | $0.00 | 310,422.0000 | 0 | 9999.99% | 0.00% |
| March 18, 2025 | Hasija Anuj | Director | A | Stock Option (Right to Buy) | 157600 | $0.00 | 157,600.0000 | 0 | 9999.99% | 0.00% |
| March 18, 2025 | Beardsley Robert A | Director | A | Stock Option (Right to Buy) | 157600 | $0.00 | 157,600.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2025 | McElhaugh Michael J. | Interim President & CEO | A | Common Shares | 177000 | $0.00 | 1,658,003.0000 | 0 | 11.95% | 0.00% |
| Feb. 14, 2025 | McElhaugh Michael J. | Interim President & CEO | A | Stock Option (Right to Buy) | 718800 | $0.00 | 718,800.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2025 | HASTINGS DAVID C | Chief Financial Officer | A | Common Shares | 90100 | $0.00 | 249,824.0000 | 0 | 56.41% | 0.00% |
| Feb. 14, 2025 | HASTINGS DAVID C | Chief Financial Officer | A | Stock Option (Right to Buy) | 365800 | $0.00 | 365,800.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2025 | Sims Karen | Chief Medical Officer | A | Common Shares | 49300 | $0.00 | 155,494.0000 | 0 | 46.42% | 0.00% |
| Feb. 14, 2025 | Sims Karen | Chief Medical Officer | A | Stock Option (Right to Buy) | 200300 | $0.00 | 200,300.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2025 | Naftzger J. Christopher | General Counsel and CCO | A | Common Shares | 54300 | $0.00 | 140,544.0000 | 0 | 62.96% | 0.00% |
| Feb. 14, 2025 | Naftzger J. Christopher | General Counsel and CCO | A | Stock Option (Right to Buy) | 220300 | $0.00 | 220,300.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | Naftzger J. Christopher | General Counsel and CCO | S | Common Shares | 11333 | $3.28 | 86,244.0000 | 0 | 11.61% | 0.00% |
| Feb. 4, 2025 | HASTINGS DAVID C | Chief Financial Officer | S | Common Shares | 22183 | $3.28 | 159,724.0000 | 0 | 12.19% | 0.00% |
| Feb. 4, 2025 | Sims Karen | Chief Medical Officer | S | Common Shares | 19348 | $3.28 | 106,194.0000 | 0 | 15.41% | 0.00% |
| Feb. 4, 2025 | McElhaugh Michael J. | Interim President & CEO | S | Common Shares | 23790 | $3.28 | 1,481,003.0000 | 0 | 1.58% | 0.00% |
| Aug. 14, 2024 | MANCHESTER KEITH S | Director | M | Stock Option (Right to Buy) | 54915 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 14, 2024 | MANCHESTER KEITH S | Director | M | Common Shares | 54915 | $0.56 | 54,915.0000 | 0 | 9999.99% | 0.00% |
| Aug. 14, 2024 | MANCHESTER KEITH S | Director | S | Common Shares | 8846 | $3.69 | 46,069.0000 | 0 | 16.11% | 0.00% |
| May 23, 2024 | Torti Frank | Director | A | Stock Option (Right to Buy) | 67000 | $0.00 | 67,000.0000 | 0 | 9999.99% | 0.00% |
| May 23, 2024 | HENRIQUES RICHARD C JR | Director | A | Stock Option (Right to Buy) | 67000 | $0.00 | 67,000.0000 | 0 | 9999.99% | 0.00% |
| May 23, 2024 | MANCHESTER KEITH S | Director | A | Stock Option (Right to Buy) | 67000 | $0.00 | 67,000.0000 | 0 | 9999.99% | 0.00% |
| May 23, 2024 | BURGESS DANIEL D | Director | A | Stock Option (Right to Buy) | 67000 | $0.00 | 67,000.0000 | 0 | 9999.99% | 0.00% |
| May 23, 2024 | Meyers James R | Director | A | Stock Option (Right to Buy) | 67000 | $0.00 | 67,000.0000 | 0 | 9999.99% | 0.00% |
| May 23, 2024 | Rewolinski Melissa | Director | A | Stock Option (Right to Buy) | 67000 | $0.00 | 67,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 2, 2024 | McElhaugh Michael J. | Interim President & CEO | S | Common Shares | 10164 | $2.31 | 1,504,793.0000 | 0 | 0.67% | 0.00% |
| Feb. 1, 2024 | Naftzger J. Christopher | General Counsel and CCO | A | Common Shares | 95100 | $0.00 | 95,100.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2024 | Naftzger J. Christopher | General Counsel and CCO | A | Stock Option (Right to Buy) | 380500 | $0.00 | 380,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2024 | Sims Karen | Chief Medical Officer | A | Common Shares | 101000 | $0.00 | 129,900.0000 | 0 | 349.48% | 0.00% |
| Feb. 2, 2024 | Sims Karen | Chief Medical Officer | S | Common Shares | 4358 | $2.31 | 125,542.0000 | 0 | 3.35% | 0.00% |
| Feb. 1, 2024 | Sims Karen | Chief Medical Officer | A | Stock Option (Right to Buy) | 403900 | $0.00 | 403,900.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2024 | HASTINGS DAVID C | Chief Financial Officer | A | Common Shares | 112500 | $0.00 | 191,500.0000 | 0 | 142.41% | 0.00% |
| Feb. 2, 2024 | HASTINGS DAVID C | Chief Financial Officer | S | Common Shares | 9593 | $2.31 | 181,907.0000 | 0 | 5.01% | 0.00% |
| Feb. 1, 2024 | HASTINGS DAVID C | Chief Financial Officer | A | Stock Option (Right to Buy) | 450000 | $0.00 | 450,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2024 | Sofia Michael J. | Chief Scientific Officer | A | Common Shares | 109500 | $0.00 | 1,662,265.0000 | 0 | 7.05% | 0.00% |
| Feb. 2, 2024 | Sofia Michael J. | Chief Scientific Officer | S | Common Shares | 9982 | $2.31 | 1,652,283.0000 | 0 | 0.60% | 0.00% |
| Feb. 1, 2024 | Sofia Michael J. | Chief Scientific Officer | A | Stock Option (Right to Buy) | 437800 | $0.00 | 437,800.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2024 | McElhaugh Michael J. | Interim President & CEO | A | Common Shares | 123800 | $0.00 | 1,514,957.0000 | 0 | 8.90% | 0.00% |
| Feb. 1, 2024 | McElhaugh Michael J. | Interim President & CEO | A | Stock Option (Right to Buy) | 495100 | $0.00 | 495,100.0000 | 0 | 9999.99% | 0.00% |
| July 12, 2023 | Rewolinski Melissa | Director | A | Stock Option (Right to Buy) | 110000 | $0.00 | 110,000.0000 | 0 | 9999.99% | 0.00% |
| July 10, 2023 | Sims Karen | Chief Medical Officer | A | Stock Option (Right to Buy) | 153640 | $0.00 | 153,640.0000 | 0 | 9999.99% | 0.00% |
| July 10, 2023 | Naftzger J. Christopher | General Counsel and CCO | A | Stock Option (Right to Buy) | 500000 | $0.00 | 500,000.0000 | 0 | 9999.99% | 0.00% |
| May 24, 2023 | MANCHESTER KEITH S | Director | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 0 | 9999.99% | 0.00% |
| May 24, 2023 | Torti Frank | Director | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 0 | 9999.99% | 0.00% |
| May 24, 2023 | Meyers James R | Director | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 0 | 9999.99% | 0.00% |
| May 24, 2023 | BURGESS DANIEL D | Director | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 0 | 9999.99% | 0.00% |
| May 24, 2023 | HENRIQUES RICHARD C JR | Director | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2023 | HASTINGS DAVID C | Chief Financial Officer | A | Stock Option (Right to Buy) | 316000 | $0.00 | 316,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2023 | Collier William H. | President and CEO | A | Common Shares | 216500 | $0.00 | 216,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2023 | Collier William H. | President and CEO | A | Stock Option (Right to Buy) | 866000 | $0.00 | 866,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2023 | Howard Elizabeth | EVP, GC, Compliance | A | Common Shares | 69700 | $0.00 | 86,024.0000 | 0 | 426.98% | 0.00% |
| Feb. 1, 2023 | Howard Elizabeth | EVP, GC, Compliance | A | Stock Option (Right to Buy) | 278700 | $0.00 | 278,700.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2023 | McElhaugh Michael J. | Chief Business Officer | A | Stock Option (Right to Buy) | 334700 | $0.00 | 334,700.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2023 | McElhaugh Michael J. | Chief Business Officer | A | Common Shares | 83700 | $0.00 | 1,391,157.0000 | 0 | 6.40% | 0.00% |
| Feb. 1, 2023 | Sofia Michael J. | Chief Scientific Officer | A | Common Shares | 82200 | $0.00 | 1,552,765.0000 | 0 | 5.59% | 0.00% |
| Feb. 1, 2023 | Sofia Michael J. | Chief Scientific Officer | A | Stock Option (Right to Buy) | 328700 | $0.00 | 328,700.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2023 | HASTINGS DAVID C | Chief Financial Officer | A | Common Shares | 79000 | $0.00 | 79,000.0000 | 0 | 9999.99% | 0.00% |